aibio
Financings ·
GH Research reports $111.2 million net proceeds from April 2026 share offering
The April offering sold 6,527,779 shares at $18.00. The interim report does not name the underwriters, and the six-month loss rose to $34,113 thousand.
GHRS GH Research PLC
GH Research (GHRS) news GHRS offering news
Latest GH Research news
We have not published a story on GH Research yet. When there is news, it will appear here.
What GH Research does
GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for depression, with an initial focus on treatment-resistant depression, or TRD. Its lead candidate, GH001, is an inhalable mebufotenin product, and its second candidate, GH002, is an intravenous mebufotenin product. GH001 has completed two Phase 1 healthy volunteer trials, a Phase 1/2 trial in patients with TRD, and a randomized, double-blind, placebo-controlled Phase 2b trial with an open-label extension. The company is developing a proprietary aerosol delivery device with a contract development and manufacturing organization for a pivotal program it expects to start in 2026. The FDA placed the GH001 IND on clinical hold in 2023, and the hold was lifted in December 2025 after the company submitted a complete response in November 2025. The company estimates there are approximately nine million TRD patients in the United States and Europe, and it notes that the two approved pharmacotherapies for TRD have mixed efficacy and potential side effects. GH Research was incorporated in Ireland in 2021 as a holding company for GH Research Ireland Limited.
| Product or program | What it is | Stage |
|---|---|---|
| GH001 | Inhalable mebufotenin for treatment-resistant depression | Phase 2b completed; pivotal trial expected to start in 2026 |
| GH002 | Intravenous mebufotenin candidate for psychiatric and neurological disorders | dose-ranging clinical pharmacology trial completed in healthy volunteers |
GH Research annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $38.8 million | $35.0 million |
| Net income (loss) | -$48.3 million | -$39.0 million |
| Cash from operations | -$43.6 million | -$42.3 million |
| Cash and equivalents | $246.3 million | $100.8 million |
| Short-term investments | $0 | $19.4 million |
Questions about GH Research
Has GH Research raised money recently?
Our latest story on this, dated Aug 6, 2026: "GH Research reports $111.2 million net proceeds from April 2026 share offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of GH Research?
GH Research PLC trades under the ticker GHRS on NASDAQ.
Where is GH Research listed?
GH Research PLC is listed on NASDAQ. Our directory also records these other listings: GETTEX:1KA; LS:A3CUAZ; LSX:A3CUAZ.
What is the SEC CIK of GH Research?
The SEC Central Index Key (CIK) for GH Research PLC is 1855129. Its filings are on SEC EDGAR.
How many shares does GH Research have outstanding?
62,029,395 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05.
Which country or territory is GH Research listed under?
Our directory records GH Research PLC under Ireland.
What does GH Research do?
Our directory classifies GH Research PLC as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
What is the ISIN of GH Research?
The ISIN recorded for GH Research PLC is IE000GID8VI0.
Does aibio.space cover GH Research?
aibio.space lists GH Research PLC among 2,820 public biotech companies and publishes its news here as stories appear.
Where is GH Research incorporated?
SEC records list its state or country of incorporation as L2.
What does GH Research develop?
GH Research PLC is a clinical-stage biopharmaceutical company developing treatments for depression, with an initial focus on treatment-resistant depression, or TRD. Its lead candidate, GH001, is an inhalable mebufotenin product, and its second candidate, GH002, is an intravenous mebufotenin product.
What is GH001 from GH Research?
GH001: Inhalable mebufotenin for treatment-resistant depression Stage: Phase 2b completed; pivotal trial expected to start in 2026.
What is GH002 from GH Research?
GH002: Intravenous mebufotenin candidate for psychiatric and neurological disorders Stage: dose-ranging clinical pharmacology trial completed in healthy volunteers.
Is GH Research profitable?
GH Research PLC reported a net loss of $48.3 million for the fiscal year ended Dec 31, 2025, and used $43.6 million of cash in operations, per its annual report to the SEC.
How much does GH Research spend on research and development?
$38.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: GH Research
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- GH Research PLC
- CIK
- 1855129
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- GHRS (Nasdaq)
- State or country of incorporation
- L2
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer<br>Emerging growth company
- Business address
- JOSHUA DAWSON HOUSE, DUBLIN 2, Ireland, D02 RY95
- Phone
- 353 1 437 8334
- Shares outstanding
- 62,029,395 as of 2025-12-31 (20-F filed 2026-03-05)
Recent filings
Listing details
- Company
- GH Research PLC
- Ticker
- GHRS
- Listing
- NASDAQ
- Country or territory
- Ireland
- Business scope
- Biopharma / pharmaceutical profile checked
- ISIN
- IE000GID8VI0
- Other listed symbols
- GETTEX:1KA; LS:A3CUAZ; LSX:A3CUAZ
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction